Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1997-09-10
1999-10-12
Jones, Dwayne C.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
548486, A01N 4338
Patent
active
059656000
DESCRIPTION:
BRIEF SUMMARY
TECHNICAL FIELD
The present invention relates to a novel 3-(bis-substituted phenylmethylene)oxindole derivative and pharmaceuticals containing this compound.
BACKGROUND ART
Fibrosis of cells that brings about functional disorders of various organs and tissue is a great clinical problem in the alleviation of inflammation and the curing of wounds in organs or tissue. In joints, fibrosis of cells causes articular rheumatism, and in the liver, progress of cellular fibrosis leads to hepatic cirrhosis, causing jaundice and hypoproteinemia and eventually leading to liver failure. In blood vessels, fibrosis of vascular walls causes loss of elasticity of the walls, leading to arteriosclerosis. The first step of fibrosis is granulation, and therefore, it is considered that articular rheumatism,-hepatic cirrhosis, arteriosclerosis, etc. would be successfully treated if granulation could be inhibited.
In the development of pharmaceuticals, compounds having liver toxicity are problematic for successful development. In Nature No. 283, 397-398 (1980), it is reported that increased production of peroxisome, which causes hepatomegaly, is a carcinogenetic factor.
Therefore, there is strong demand for pharmaceuticals which exhibit excellent granulation inhibiting activity with minimal liver toxicity and which are thus advantageously used in clinical situations.
Analogs of a 3-(bis-substituted phenylmethylene)-oxindole derivative, which is the compound of the present invention, are disclosed in Ber., 96 (1963), 3328-37, Japanese Patent Publication (kokoku) No. 43-3195, and in U.S. Pat. No. 3,428,649. Of the analogs, 3-[bisphenylmethylene]-oxindole (compound a) of the following formula, disclosed in Ber., 96 (1963), 3328-37 is particularly close to the compounds of the present invention. However, that compound is merely disclosed as a synthesis intermediate, and no pharmacological activity is described at all. ##STR2##
Japanese Patent Publication (kokoku) No. 43-3195 discloses, as a synthesis intermediate, an oxindole derivative represented by the following formula (2): ##STR3## (wherein each of R.sup.1 and R.sup.2 represents lower alkyl, aryl, or pyridyl; and R.sup.3 represents a hydrogen atom or lower alkyl).
However, the disclosure of 3-(bis-substituted phenylmethylene)oxindole derivative in that publication is in fact directed only to specific compounds in which R.sup.3 is a methyl group and R.sup.1 and R.sup.2 are both unsubstituted phenyl groups, and to use as synthesis intermediates.
Accordingly, the object of the present invention is to provide a novel oxindole derivative which exhibits excellent granulation inhibiting activity while providing minimal liver toxicity and which is thus advantageously used as a pharmaceutical.
DISCLOSURE OF THE INVENTION
Under the above-described circumstances, the present inventors have conducted careful studies, and have found that the 3-(bis-substituted phenylmethylene)oxindole derivative represented by formula (1) exhibits excellent granulation inhibitory activity while providing minimal liver toxicity and can thus be advantageously used as a pharmaceutical, leading to completion of the invention.
Accordingly, the present invention provides an oxindole derivative represented by formula (1): ##STR4## (wherein R represents a methyl group or a methoxy group).
The present invention also provides a pharmaceutical containing as the active ingredient the oxindole derivative (1)
The present invention also provides a granulation inhibitor containing as the active ingredient the oxindole derivative (1).
The present invention also provides a pharmaceutical composition containing the oxindole derivative (1) and a pharmacologically acceptable carrier.
The present invention also provides a granulation inhibitor composition containing the oxindole derivative (1) and a pharmacologically acceptable carrier.
The present invention further provides use, as a pharmaceutical, of the oxindole derivative (1).
The present invention still further provides use, as a granulation inhibitor, of the oxindole
REFERENCES:
patent: 3413299 (1968-11-01), Anthony
patent: 3428649 (1969-02-01), Plostnicks
Chemical abstract, vol. 60:4086a(Ber., 96(1963), 3328-37), 1996.
Asao Tetsuji
Hagiwara Yu-ichi
Kitade Makoto
Sato Atsushi
Yamazaki Yasundo
Jones Dwayne C.
Taiho Pharmaceutical Co. Ltd.
LandOfFree
3-(bis-substituted phenylmethylene) oxindole derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 3-(bis-substituted phenylmethylene) oxindole derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 3-(bis-substituted phenylmethylene) oxindole derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-653038